Pign With Aki

Disclaimer: This information is intended for educational purposes and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Clinicians must exercise their independent medical judgment in all patient care decisions. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to patient care.

Overview

• Definition: Post-Streptococcal Glomerulonephritis (PSGN), often abbreviated as PIGN, is an immune-mediated renal disorder characterized by acute inflammation of the glomeruli, typically following an infection with specific nephritogenic strains of Group A Streptococcus (GAS) (Streptococcus pyogenes). Acute Kidney Injury (AKI) in this context refers to a sudden decline in kidney function, typically manifested by an increase in serum creatinine and/or a decrease in urine output, occurring as a direct consequence of the glomerular injury in PSGN.
• Epidemiology: PSGN is most common in children aged 5-15 years, with a peak incidence between 6 and 8 years. It is less common in infants and adults. The incidence has declined in developed countries due to improved hygiene and access to healthcare but remains a significant cause of AKI in children in developing nations. PSGN typically occurs 1-3 weeks after streptococcal pharyngitis or 3-6 weeks after streptococcal skin infection (impetigo).
• Classification: While PSGN itself is a specific diagnosis, its clinical presentation can range from asymptomatic microscopic hematuria to severe acute nephritic syndrome with AKI. The severity of AKI can be classified using criteria like KDIGO (e.g., Stage 1, 2, 3 based on creatinine increase and/or urine output reduction). PSGN is a form of acute diffuse proliferative glomerulonephritis.

Pathophysiology

• Mechanism: PSGN is a classic example of an immune complex-mediated disease. Following infection with nephritogenic GAS strains, specific streptococcal antigens (e.g., streptococcal pyrogenic exotoxin B (SPEB)/nephritis-associated plasmin receptor (NAPB), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), endostreptosin) are released. These antigens are thought to interact with host antibodies to form immune complexes that become trapped in the glomeruli. Alternatively, some streptococcal antigens may bind directly to the glomerulus, where they then serve as in situ targets for circulating antibodies. The deposition of these immune complexes (predominantly IgG and C3) in the subepithelial space and mesangium activates the complement cascade, primarily via the alternative pathway, leading to localized inflammation, proliferation of glomerular cells, and infiltration by inflammatory cells (neutrophils, monocytes). This inflammatory response results in glomerular damage, leading to reduced glomerular filtration rate (GFR), increased vascular permeability (causing proteinuria and hematuria), and sodium and water retention, ultimately manifesting as AKI, edema, and hypertension.
• Risk Factors:
  • Recent infection with nephritogenic strains of Group A Streptococcus (e.g., M types 1, 2, 4, 12, 18, 25, 49, 55, 57, 60).
  • Age: Children 5-15 years are most susceptible.
  • Crowded living conditions and poor hygiene.
  • Geographic location: Higher incidence in developing countries and tropical climates.
  • Underlying immune predisposition (not well defined).
• Protective Factors:
  • Improved hygiene and sanitation.
  • Access to healthcare and prompt treatment of streptococcal infections (antibiotic treatment of pharyngitis prevents rheumatic fever but does not consistently prevent PSGN; early treatment of impetigo may reduce PSGN risk).
  • Public health measures to control streptococcal outbreaks.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Typically appear 1-3 weeks after pharyngitis or 3-6 weeks after skin infection.
  • Hematuria: Gross (cola-colored, smoky, or reddish-brown urine) or microscopic. Present in nearly all cases.
  • Edema: Periorbital (especially in the morning) and/or dependent edema (lower extremities, sacrum) due to fluid retention.
  • Hypertension: Mild to severe, resulting from fluid overload and possibly increased renin activity.
  • Oliguria: Reduced urine output, indicating AKI.
• Early Signs:
  • Fatigue, lethargy.
  • Mild periorbital edema.
  • Darkening of urine color.
  • Headache.
• Advanced Signs: Manifestations of severe AKI and fluid overload.
  • Anasarca (generalized severe edema).
  • Severe hypertension, potentially leading to hypertensive encephalopathy (headache, vomiting, visual disturbances, altered mental status, seizures).
  • Symptoms of pulmonary edema/heart failure (dyspnea, orthopnea, cough, crackles).
  • Frank oliguria or anuria.
  • Uremic symptoms (nausea, vomiting, anorexia, confusion) in severe AKI.
• Atypical Presentations:
  • Asymptomatic microscopic hematuria and proteinuria (detected incidentally).
  • Rapidly Progressive Glomerulonephritis (RPGN) in a small percentage, with swift decline in renal function.
  • PSGN without clear history of antecedent streptococcal infection.

Physical Examination

• Inspection:
  • Periorbital edema, facial puffiness.
  • Pitting edema of the lower extremities, sacrum, or generalized anasarca.
  • Pallor (may indicate anemia or fluid retention).
  • Signs of antecedent infection (e.g., pharyngeal erythema, tonsillar exudates if recent pharyngitis; impetiginous skin lesions or scars if recent pyoderma).
  • Jugular venous distension (JVD) as a sign of fluid overload.
  • Evidence of pulmonary congestion (e.g., tachypnea, use of accessory muscles).
• Palpation:
  • Pitting edema.
  • Peripheral pulses may be bounding due to fluid overload.
  • Abdominal examination may reveal ascites or hepatomegaly in severe fluid overload.
• Special Tests:
  • Blood Pressure Measurement: Essential; often elevated. Document baseline and serial measurements.
  • Cardiopulmonary Auscultation: Crackles or rales (pulmonary edema), S3 gallop (heart failure).
  • Fundoscopy: May reveal hypertensive retinopathy (e.g., arteriolar narrowing, hemorrhages, papilledema) in severe cases.

Diagnostic Approach

History Taking

• Key Questions:
  • Recent infection: History of sore throat (pharyngitis) 1-3 weeks prior, or skin infection (impetigo, pyoderma) 3-6 weeks prior. Inquire about exposure to similar illnesses.
  • Urinary changes: Onset, color (cola-colored, smoky), amount (oliguria), frequency.
  • Edema: Location (periorbital, dependent), time of day, progression.
  • Systemic symptoms: Headache, fatigue, nausea, vomiting, decreased appetite.
  • Neurological symptoms: Vision changes, confusion, seizures (suggestive of hypertensive encephalopathy).
  • Cardiopulmonary symptoms: Shortness of breath, cough, orthopnea (suggestive of fluid overload/pulmonary edema).
  • Medication history: Especially nephrotoxic drugs.
  • Family history: Renal disease, autoimmune conditions.
• Red Flags: Oliguria/anuria, severe uncontrolled hypertension, altered mental status, seizures, severe dyspnea/pulmonary edema. These warrant immediate medical attention and may indicate severe AKI requiring intensive management or renal replacement therapy.

Laboratory Tests

• First-Line:
  • Urinalysis with Microscopy:
    • Hematuria: Gross or microscopic (≥3 RBCs/HPF). Dysmorphic red blood cells and red blood cell casts are highly suggestive of glomerular origin.
    • Proteinuria: Typically non-nephrotic range (<3.5 g/day, often 0.5-2 g/day). May be higher in severe cases.
    • Specific Gravity: Often elevated.
    • Leukocyturia: May be present, usually sterile.
  • Serum Creatinine (sCr) & Blood Urea Nitrogen (BUN): Elevated, reflecting AKI. Monitor trends.
  • Serum Electrolytes: May reveal hyperkalemia, hyponatremia, hyperphosphatemia, and metabolic acidosis depending on AKI severity.
  • Complement Levels:
    • C3: Decreased in approximately 90% of PSGN cases. Returns to normal within 6-8 weeks in most patients. Persistent low C3 beyond 8 weeks should prompt consideration of alternative diagnoses (e.g., membranoproliferative glomerulonephritis, lupus nephritis).
    • C4: Usually normal in PSGN, helping to differentiate from classical pathway complement disorders (e.g., lupus nephritis).
  • Evidence of Recent Streptococcal Infection:
    • Antistreptolysin O (ASO) Titer: Elevated in 80% of pharyngitis-related PSGN. Peaks 2-4 weeks after infection.
    • Anti-DNase B Titer: Elevated in 90% of pharyngitis-related and 70% of skin infection-related PSGN. More reliable for skin infections as ASO response may be blunted.
    • Streptozyme Test: A multi-antibody test (ASO, anti-DNase B, antihyaluronidase, antistreptokinase) useful for detecting recent GAS infection.
    • Throat swab/skin culture: May be positive for GAS, but often negative by the time PSGN manifests.
  • Complete Blood Count (CBC): May show mild anemia (due to hemodilution, fluid retention, or uremia) and leukocytosis with left shift (if concurrent infection).
• Confirmatory:
  • Kidney Biopsy: Not routinely performed in classic cases of PSGN, especially in children, due to its generally favorable prognosis and the invasiveness of the procedure. Indicated in specific situations:
    • Atypical presentation (e.g., absence of preceding infection, normal C3 levels, older age).
    • Persistent oliguria/anuria or rapidly progressive AKI despite supportive care.
    • Lack of clinical improvement or worsening renal function after 1-2 weeks.
    • Persistent low C3 beyond 8 weeks.
    • Histological findings typically include diffuse proliferative glomerulonephritis with characteristic subepithelial immune deposits ("humps") on electron microscopy, and granular C3 and IgG deposition on immunofluorescence.
• Monitoring:
  • Daily weights, intake/output, blood pressure.
  • Serial sCr, BUN, and electrolytes to track AKI resolution and monitor for complications.
  • Repeat urinalysis to track resolution of hematuria and proteinuria.
  • Repeat C3 levels at 6-8 weeks to confirm normalization.

Imaging

• Recommended:
  • Renal Ultrasound: To assess kidney size and echogenicity, rule out urinary tract obstruction, and exclude chronic kidney disease (e.g., small, scarred kidneys). In acute PSGN, kidneys are usually normal sized or slightly enlarged.
  • Chest X-ray: If pulmonary edema or cardiac decompensation is suspected, to assess for cardiomegaly, pulmonary vascular congestion, and pleural effusions.
• Advanced: Generally not required for the diagnosis or management of typical PSGN with AKI.

Management

Acute Management (Focus on AKI and complications)

• Immediate: Address life-threatening complications related to fluid overload and severe hypertension.
  • Severe Hypertension: Target blood pressure reduction by 25% within the first few hours.
    • IV Antihypertensives: For hypertensive encephalopathy, acute heart failure, or severe symptomatic hypertension. Examples:
      • Labetalol: 0.2-1 mg/kg IV bolus (max 40 mg), repeat every 10-15 min, then infusion 0.25-3 mg/kg/hr.
      • Nicardipine: 0.5-5 mcg/kg/min IV infusion.
      • Sodium Nitroprusside: 0.5-10 mcg/kg/min IV infusion (caution with prolonged use due to thiocyanate toxicity).
    • Oral Antihypertensives: For less severe, but significant, hypertension.
      • Nifedipine (extended-release): 0.25-0.5 mg/kg/dose orally every 6-8 hours (max 10-20 mg/dose).
      • Hydralazine: 0.5-1 mg/kg/dose orally/IV every 6-8 hours.
      • ACE inhibitors and ARBs should be used with caution in severe AKI or hyperkalemia due to risk of worsening renal function and hyperkalemia.
  • Pulmonary Edema/Acute Heart Failure:
    • Oxygen supplementation.
    • Diuretics: Furosemide 1-2 mg/kg IV (may need higher doses in AKI, e.g., 5-10 mg/kg, due to reduced efficacy) repeated as needed.
    • Fluid and Sodium Restriction: Crucial.
  • Hyperkalemia:
    • Calcium Gluconate: 0.5-1 mL/kg of 10% solution IV over 5-10 min (for cardiac membrane stabilization if ECG changes).
    • Insulin/Dextrose: Regular insulin 0.1 U/kg IV with Dextrose 0.5-1 g/kg IV.
    • Beta-agonists: Albuterol nebulization.
    • Sodium Polystyrene Sulfonate (Kayexalate): 1 g/kg orally/rectally (takes hours).
  • Severe Metabolic Acidosis: Sodium bicarbonate IV if pH <7.1 and evidence of bicarbonate-responsive acidosis, particularly with severe hyperkalemia.
  • Seizures: Benzodiazepines (e.g., Lorazepam 0.05-0.1 mg/kg IV) to abort acute seizures.
• Stabilization:
  • Fluid and Sodium Restriction: Limit fluid intake to insensible losses (e.g., 400 mL/m²/day or 500 mL/day for adults) plus urine output. Sodium restriction to <2 g/day.
  • Diuretics: Continue loop diuretics if fluid overload persists and urine output is adequate.
  • Antibiotics: Administer antibiotics to eradicate any residual streptococcal infection, though this does not alter the course of established glomerulonephritis.
    • Penicillin V: 250-500 mg orally TID for 10 days.
    • Benzathine Penicillin G: 600,000 units (for children <27 kg) or 1.2 million units (for children >27 kg and adults) IM once.
    • For penicillin-allergic patients: Erythromycin 250 mg orally QID for 10 days.
• Emergency:
  • Renal Replacement Therapy (RRT): Indicated for refractory fluid overload, severe hyperkalemia, severe metabolic acidosis, uremic encephalopathy, pericarditis, or uncontrolled hypertension despite maximal medical therapy. Hemodialysis is usually preferred, but peritoneal dialysis can also be used, especially in children.

Chronic Management

• Pharmacological:
  • Antihypertensives: Continue as needed to maintain target blood pressure (e.g., <120/80 mmHg or age-appropriate targets for children). Calcium channel blockers, diuretics, beta-blockers are often used. ACE inhibitors or ARBs can be considered if proteinuria persists and AKI has resolved, with careful monitoring of kidney function and potassium.
  • Diuretics: May be continued at lower doses if mild fluid retention or hypertension persists.
• Non-pharmacological:
  • Dietary Modifications: Maintain sodium restriction if hypertension or fluid retention persists. Potassium restriction if hyperkalemia is an issue.
  • Activity: Rest is recommended during the acute phase. Resume normal activities as symptoms improve and blood pressure is controlled.
• Monitoring:
  • Regular follow-up appointments (e.g., weekly initially, then monthly, then less frequently).
  • Monitor blood pressure, urinalysis (for hematuria, proteinuria), serum creatinine, and C3 levels.
  • Long-term follow-up (up to 5-10 years or more) is recommended due to the small risk of persistent hypertension, proteinuria, or progression to chronic kidney disease (CKD), particularly in adults.

Treatment Algorithms

• First-Line:
  1. Confirm diagnosis (history, labs including C3, ASO/Anti-DNase B, urinalysis).
  2. Supportive care: Fluid and sodium restriction.
  3. Manage hypertension with oral or IV antihypertensives.
  4. Manage fluid overload with diuretics.
  5. Administer antibiotics for residual streptococcal infection.
  6. Monitor electrolytes, sCr, BUN, urine output, and blood pressure closely.
• Second-Line:
  1. If complications (refractory fluid overload, severe hyperkalemia, severe acidosis, uremic symptoms, uncontrolled hypertension) develop or worsen despite first-line measures, initiate Renal Replacement Therapy (RRT).
• Refractory Cases:
  1. If AKI is progressive, diagnosis is uncertain, or clinical course is atypical (e.g., persistent low C3 beyond 8 weeks, no improvement in renal function after 1-2 weeks), consider kidney biopsy to rule out other forms of glomerulonephritis or confirm severe PSGN (e.g., with extensive crescent formation, though rare).
  2. Immunosuppressive therapy is generally not indicated for typical PSGN but may be considered in biopsy-proven severe crescentic forms, though its efficacy is not well-established.

Complications

• Common:
  • Fluid overload (edema, pulmonary edema).
  • Hypertension (mild to severe).
  • Electrolyte abnormalities (hyperkalemia, hyponatremia).
  • Metabolic acidosis.
• Serious:
  • Acute heart failure (due to severe fluid overload).
  • Hypertensive crisis leading to end-organ damage (hypertensive encephalopathy with seizures, intracranial hemorrhage, acute retinal changes, acute coronary syndrome).
  • Acute respiratory distress syndrome (ARDS) secondary to pulmonary edema.
  • Uremic pericarditis or encephalopathy (in severe, prolonged AKI).
  • Rapidly Progressive Glomerulonephritis (RPGN) (rare).
• Long-term:
  • Persistent hypertension (more common in adults, 10-30%).
  • Persistent proteinuria or microscopic hematuria (up to 20% in children, higher in adults).
  • Chronic kidney disease (CKD): A small percentage (1-5% in children, higher in adults) may progress to CKD, especially if the initial presentation was severe or there are pre-existing renal issues.

Prognosis

• Factors:
  • Age: Prognosis is generally excellent in children, with >95% achieving full recovery. Adults tend to have a less favorable course, with a higher risk of persistent hypertension, proteinuria, and progression to CKD.
  • Severity of Initial AKI: More severe and prolonged AKI is associated with a greater risk of long-term complications.
  • Histological Findings: Presence of extensive crescent formation on kidney biopsy (though rare in PSGN) indicates a worse prognosis.
• Survival: Acute mortality is rare (<1%) and usually due to severe complications like uncontrolled hypertension or heart failure.
• Quality of Life: Most children recover completely and return to normal quality of life. Adults may experience persistent hypertension or proteinuria impacting long-term cardiovascular and renal health.

Prevention

• Primary:
  • Antibiotic Treatment of Streptococcal Pharyngitis: While effective in preventing acute rheumatic fever, routine antibiotic treatment of pharyngitis has not been definitively shown to prevent PSGN. It may, however, reduce the spread of nephritogenic strains.
  • Antibiotic Treatment of Streptococcal Skin Infections (Impetigo): Early and adequate antibiotic treatment of impetigo may reduce the incidence of PSGN.
  • Good Hygiene: Handwashing, bathing, and avoiding crowded living conditions are crucial, particularly in areas with high incidence of streptococcal skin infections.
• Secondary:
  • Early diagnosis and prompt supportive management of PSGN with AKI to prevent life-threatening acute complications (e.g., severe hypertension, fluid overload) and potentially mitigate the risk of long-term kidney damage.
• Tertiary:
  • Long-term monitoring for persistent proteinuria, hematuria, and hypertension after apparent recovery. Early identification and management of these residual abnormalities may prevent or slow progression to CKD.

Special Populations

• Pediatric: Children typically have a more benign course and excellent prognosis. They are, however, more susceptible to rapid development of severe fluid overload and hypertensive encephalopathy. Close monitoring and aggressive management of these complications are crucial.
• Geriatric: Older adults with PSGN often present with more severe AKI, higher rates of oliguria, and a greater propensity for complications and poorer long-term renal outcomes (higher risk of progression to CKD, increased mortality). Atypical presentations are also more common.
• Pregnancy: PSGN is rare during pregnancy. Management principles are similar, but caution is needed with certain antihypertensive agents and diuretics, balancing maternal and fetal safety. Early consultation with nephrology and obstetrics is essential.
• Comorbidities: Patients with pre-existing conditions such as diabetes, chronic kidney disease (CKD), or heart failure are at higher risk for more severe presentations, complications, and worse outcomes with PSGN and AKI. Management requires careful consideration of drug interactions and potential exacerbation of comorbidities.

Clinical Pearls

• Diagnostic: Always consider PSGN in a patient with recent pharyngitis or skin infection, cola-colored urine, edema, and hypertension. The classic laboratory findings of low C3 and normal C4, along with elevated ASO/Anti-DNase B titers, are highly suggestive. Remember that C3 normalizes within 6-8 weeks; persistent low C3 warrants further investigation. RBC casts are a strong indicator of glomerular hematuria.
• Treatment: The cornerstone of management is supportive care, primarily addressing fluid overload and hypertension. Diuretics are critical. Antibiotics are given to eradicate lingering infection and prevent spread, but do not alter the course of established PSGN. Immunosuppression is rarely indicated.
• Pitfalls:
  • Over-hydration: Aggressive fluid administration can exacerbate fluid overload, hypertension, and pulmonary edema.
  • Delayed management of severe hypertension: Can lead to devastating neurological complications (encephalopathy, seizures).
  • Misinterpreting low C3: While characteristic, persistent low C3 beyond 8 weeks should trigger a search for alternative diagnoses (e.g., lupus nephritis, membranoproliferative GN Type II).
  • Ignoring long-term follow-up: A small but significant proportion of patients, particularly adults, may develop long-term complications like hypertension and proteinuria requiring ongoing monitoring.
  • Using ACE inhibitors/ARBs initially in severe AKI: May worsen kidney function and hyperkalemia.

Recent Updates

• Guidelines: The KDIGO (Kidney Disease: Improving Global Outcomes) guidelines for Acute Kidney Injury (2012) and Glomerulonephritis provide comprehensive frameworks for the diagnosis, classification, and management of AKI and specific glomerular diseases, including PSGN. These guidelines emphasize supportive care and the importance of monitoring for complications.
• Evidence: Ongoing research continues to identify specific streptococcal antigens (e.g., streptococcal glyceraldehyde-3-phosphate dehydrogenase, streptokinase) and host immune responses that contribute to PSGN pathogenesis. This research aims to better understand disease mechanisms and potentially develop novel diagnostic or therapeutic strategies, though current management remains supportive.
• Controversies: The precise role of antibiotics in preventing PSGN following streptococcal pharyngitis remains a point of debate, with many studies suggesting minimal or no preventative effect on PSGN incidence, in contrast to the clear prevention of rheumatic fever. However, antibiotic treatment is still recommended to reduce transmission and prevent other complications.

Key References

• Guidelines:
  • KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury: Kidney International Supplements, 2012; 2(1):1-138.
  • KDIGO 2012 Clinical Practice Guideline for Glomerulonephritis: Kidney International Supplements, 2012; 2(2):139-274.
  • American Academy of Pediatrics (AAP) and Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and management of Group A Streptococcal infections.
• Studies:
  • Relevant epidemiological studies on the global burden and changing epidemiology of PSGN.
  • Research articles detailing the specific streptococcal antigens and immunological mechanisms involved in PSGN (e.g., focusing on SPEB/NAPB, GAPDH, endostreptosin).
• Reviews:
  • UpToDate: "Poststreptococcal glomerulonephritis".
  • Comprehensive review articles published in leading nephrology journals such as Kidney International, Clinical Journal of the American Society of Nephrology (CJASN), and Pediatric Nephrology.